Table 1:
Patients’ characteristics by treatment types
| Characteristics | Treatment Types |
p-valuec | |||
|---|---|---|---|---|---|
| Total | Anti-CTLA-4 (Ipilimumab or tremelimumab) | Anti-PD-1 (Nivolumab or pembrolizumab) | Combination (anti-CTLA-4+anti-PD-1) | ||
| Median age (Range) | 62.85(19-90.20) | 59.95(23-90.20) | 65.80(19-90) | 61.90(20-89) | 0.02 |
| Sex | |||||
| Male (%) | 292(66.97) | 145(67.44) | 119(67.61) | 28(62.22) | 0.77 |
| Response outcomeb | |||||
| Response (%) | 201(46.96) | 79(36.91) | 89(52.04) | 33(76.74) | |
| Institutions (N, %) | |||||
| NYULHa | 261(59.86) | 150(69.76) | 77(43.75) | 34(75.55) | |
| UCLA | 134(30.73) | 50(23.25) | 84(47.72) | 0(0.00) | |
| MGH | 41(9.41) | 15(6.99) | 15(8.53) | 11(24.44) | |
| Total | 436 | 215 | 176 | 45 | |
a
One patient was later removed in the quality control (QC) step for anti-CTLA-4 and anti-PD-1
b
There is 1 missing value in anti-CTLA-4, 6 in anti-PD-1 and 2 in combination therapy
c
Relevant patients’ characteristics (age, sex) were tested for statistical significance between treatment types. Kruskal-Wallis test was performed for the continuous variable (age); while Chi-square test was used to test the statistical difference for the categorical variable (sex).